TD Cowen analyst Steve Scala has maintained their bullish stance on ELAN stock, giving a Buy rating on March 3.
Steve Scala has given his Buy rating due to a combination of factors that indicate potential growth and profitability for Elanco Animal Health. The company is expected to experience strong revenue growth in its Pet Health segment, despite facing challenges in the Farm Animal sector. This growth is driven by innovative products like Credelio Quattro and Experior, which are projected to perform well in the market.
Looking ahead to 2026-2030, Scala anticipates solid top-line growth supported by operating leverage. The sales of key products such as Credelio Quattro, IL-31 for canine dermatology, and Bovaer are expected to reach or exceed blockbuster status, contributing to a forecasted EPS growth of 8-22% during this period. These factors collectively support the Buy rating, reflecting confidence in Elanco’s strategic positioning and future performance.
In another report released on March 3, Jefferies also maintained a Buy rating on the stock with a $18.00 price target.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ELAN in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com